INOVIO Pharmaceuticals

INOVIO reports FDA partial clinical hold for planned Phase 2/3 Trial of COVID-19 vaccine candidate INO-4800. Read more: https://bit.ly/36fwj84

INOVIO is excited to be part of the #ESMO2020 Congress with interim combo Phase 2 data in HPV-associated HNSCC. See more: https://bit.ly/3hFraIt #DNAMedicine #HPV #cancer

Recurrent Respiratory Papillomatosis (#RRP) is a rare, debilitating, and potentially life-threatening disease caused by #HPV genotypes 6/11. RRP causes noncancerous growths leading to airway obstructions and can occasionally progress to cancer. We’re on a mission to use #DNAMedicines to provide treatment options to people like Robb who live with RRP. See his story here.

Now more than ever, all eyes are on the importance of vaccinations. August is National Immunization Awareness Month and an important reminder of the significant advancements we’ve seen in vaccination development because of #COVID19. Learn more about our COVID-19 DNA vaccine candidate: https://bit.ly/3iR0VQ7 #DNAVaccines #DNAMedicines #Vax2Protect

INOVIO’s first-of-their-kind #DNAMedicines are delivered directly into cells so that the body fights disease from within by producing a natural immune response robust enough to potentially treat or prevent diseases like precancerous cervical dysplasia, an #HPV 16/18-related disease. #DNAVaccines

The World Health Organization (WHO) will meet over the next few days to discuss the adoption of #DNAVaccines guidelines to assure the quality, safety and efficacy of DNA vaccine candidates like INO-4800. This is an important step forward in powering a new decade of #DNAMedicines. In this committee briefing document, learn more about the history of DNA vaccines and the potential they have to fight viruses: https://bit.ly/3g7VHOm

Women with vulvar dysplasia (HSIL), a precancerous condition caused by HPV types 16 and/or 18, currently have no long-term treatment options and often require surgery. There is a critical gap that a potential DNA immunotherapy like VGX-3100 could fill. Read more about our #DNAImmunotherapies in this HPV World article by Dr. Prakash K. Bhuyan, INOVIO VP of Clinical Development, HPV Therapeutics: https://bit.ly/3iC5iyA #DNAMedicines

Animal challenge data for INOVIO’s INO-4800 shows immune responses against the G614 variant of #COVID19, which has emerged with greater infectivity, causing >80% of newly circulating SARS-CoV-2 virus cases worldwide. Learn more: https://bit.ly/2PjRcVE #DNAMedicines #DNAVaccines

Animal challenge data is currently the closest thing we have to testing a #COVID19 vaccine’s efficacy when confronting a live virus. #DNAMedicines #DNAVaccines

New research suggests the important role T cell responses could have in developing effective vaccines against #COVID19. Learn more here: https://bit.ly/39ToQeH #DNAMedicines #DNAVaccines

#ICYMI: INOVIO recently announced our DNA vaccine INO-4800 targeting SARS-CoV-2, the virus that causes #COVID19, demonstrated long-term protection in non-human primates challenged with SARS-CoV-2, 13 weeks after the last vaccination. Read more: https://bit.ly/2D6Ax5L #DNAMedicines #DNAVaccines

Join us in thanking Dr. Kate Broderick, INOVIO SVP and R&D Lead, and our entire INOVIO team for their tireless and extraordinary efforts to develop a DNA vaccine candidate to combat #COVID19 with INO-4800. #DNAVaccines #DNAMedicines because the world can’t wait.

Over the last decade, INOVIO has led the field in demonstrating how #DNAMedicines can be rapidly developed and delivered to produce safe and robust immune responses. We’re proud of our team and excited for what’s next. #DNAVaccines #DNAImmunotherapies

The second quarter further demonstrated the impact DNA medicines could have on the world. We’re excited to share milestones here for our #DNAMedicines, #DNAVaccines and #DNAImmunoterapies. See more here and thank you for being part of our mission: https://bit.ly/30GOEaO